Mary Chapman, features writer —

Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. She’s won a Society of Professional Journalists award for outstanding reporting.

Articles by Mary Chapman

RoslinCT to manufacture CRISPR-based gene therapy Casgevy

RoslinCT will manufacture the groundbreaking new gene therapy Casgevy (exagamglogene autotemcel) for sickle cell disease (SCD) patients in the U.S. and U.K. RoslinCT, a cell and gene therapy contract development and manufacturing company, has facilities in Edinburgh, Scotland and Hopkinton, Massachusetts. The company worked with Vertex…

Mount Sinai gets $12M NIH grant for study to personalize treatments

A $12.2-million grant awarded to the New York-based Mount Sinai Health System will enable a nationwide observational study to help better personalize sickle cell disease (SCD) treatments. “Sickle cell traditionally has been a neglected disease, but it benefited from a flurry of innovation over the last decade and…

My Special Aflac Duck brings cheer to SCD patients

To help heighten awareness of sickle cell disease (SCD) and pediatric cancers, while bringing comfort and relief to patients, the supplemental insurance provider Aflac recently gifted its My Special Aflac Duck social robot to children at the University of New Mexico (UNM) Children’s Hospital in Albuquerque. The delivery…

US company expands to Africa to speed SCD therapy development

To help bring new therapies more quickly and cost effectively to those with sickle cell disease (SCD) in sub-Saharan countries — where patients bear a significantly high SCD burden — the U.S.-based biotechnology company Functional Fluidics is planning to expand its operations into Africa. The expansion is expected…

New app for sickle cell disease helps patients manage pain

A new, interactive application touted as the first of its kind can help people with sickle cell disease (SCD) learn about and communicate with their care team about their pain attacks. Called Pinpoint, the app is the product of a partnership between healthcare purchased services provider HPC…

Syros seeking new partner for its SCD program after Pfizer ends deal

Pfizer has decided to end a treatment discovery program with Syros Pharmaceuticals that it inherited after acquiring Global Blood Therapeutics (GBT) last year, leaving Syros to seek another partner for the program, which targets two blood disorders, including sickle cell disease (SCD). The agreement termination was announced…